{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:35:29Z","timestamp":1777930529168,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T00:00:00Z","timestamp":1686960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T00:00:00Z","timestamp":1686960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Royal Library, Copenhagen University Library"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction and hypothesis<\/jats:title>\n                <jats:p>We aimed to examine the risk of bleeding in female patients undergoing intravesical onabotulinumtoxinA (BTX-A) treatments and provide clinical recommendations for the perioperative management of patients on antithrombotic therapy prior to BTX-A treatments.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a retrospective cohort of Danish female patients, who had their first BTX-A treatment because of an overactive bladder at the Department of Gynecology and Obstetrics, Herlev and Gentofte University Hospital, between January 2015 and December 2020. Data extraction was from an electronic medical journal system. BTX-A, Botox\u00ae Allergan was injected in the detrusor at 10\u201320 sites. Significant bleeding during or after a BTX-A treatment was defined as persistent macroscopic hematuria. Bleeding reporting was based on information obtained from journal notes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We included 400 female patients, who had a total of 1,059 BTX-A treatments. Median age at first BTX-A treatment was 70 years (IQR 21), and median number of BTX-A treatments was 2 (range 1\u201311). In total, 27.8% (<jats:italic>n<\/jats:italic>=111) received antithrombotic therapy. Within this group, 30.6% and 69.4% were on anticoagulant and antiplatelet therapy. No cases of hematuria were reported in our cohort. We found that no patients stopped their antithrombotic therapy, were bridged, or monitored by International Normalized Ration (INR) levels.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We suggest that BTX-A treatments might be classified as low-risk procedures. Discontinuation of antithrombotic therapy is not required in the perioperative management of this patient group.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00192-023-05579-1","type":"journal-article","created":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T14:01:47Z","timestamp":1687010507000},"page":"2581-2585","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Bleeding risk in female patients undergoing intravesical injection of onabotulinumtoxinA for overactive bladder: a Danish retrospective cohort study"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4570-7953","authenticated-orcid":false,"given":"Meryam","family":"El Issaoui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Elissaoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlene","family":"Elmelund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Klarskov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,17]]},"reference":[{"key":"5579_CR1","doi-asserted-by":"crossref","unstructured":"Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev. 2011;(12)CD005493.","DOI":"10.1002\/14651858.CD005493.pub3"},{"key":"5579_CR2","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.amjmed.2012.04.005","volume":"125","author":"J Donze","year":"2012","unstructured":"Donze J, Rodondi N, Waeber G, Monney P, Cornuz J, Aujesky D. Scores to predict major bleeding risk during oral anticoagulation therapy: a prospective validation study. Am J Med. 2012;125:1095\u2013102.","journal-title":"Am J Med"},{"key":"5579_CR3","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s11239-009-0308-4","volume":"27","author":"SM Gharacholou","year":"2009","unstructured":"Gharacholou SM, Becker RC. Hemostasis and thrombosis in older adults. J Thromb Thrombolysis. 2009;27:249\u201351.","journal-title":"J Thromb Thrombolysis"},{"key":"5579_CR4","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1093\/eurheartj\/ehac270","volume":"43","author":"S Halvorsen","year":"2022","unstructured":"Halvorsen S, Mehilli J, Cassese S, et al. ESC guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022;43:3826\u2013924.","journal-title":"Eur Heart J"},{"key":"5579_CR5","first-page":"429","volume":"75","author":"FLJ Visseren","year":"2022","unstructured":"Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Rev Esp Cardiol (Engl Ed). 2022;75:429.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"5579_CR6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3390\/ijms19020481","volume":"19","author":"C Izzo","year":"2018","unstructured":"Izzo C, Carrizzo A, Alfano A, et al. The impact of aging on cardio and cerebrovascular diseases. Int J Mol Sci. 2018;19:481.","journal-title":"Int J Mol Sci"},{"key":"5579_CR7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1177\/2051415817728612","volume":"11","author":"ADC Kanthabalan","year":"2017","unstructured":"Kanthabalan ADC. Guideline for stopping anticoagulants prior to urological procedures. J Clin Urol. 2017;11:271\u20139.","journal-title":"J Clin Urol"},{"key":"5579_CR8","unstructured":"Dansk Selskab for Trombose og H\u00e6mostase. Available from: https:\/\/dsth.dk\/. Accessed 21 February 2023"},{"key":"5579_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/00365590601068835","volume":"41","author":"I Ehren","year":"2007","unstructured":"Ehren I, Volz D, Farrelly E, et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol. 2007;41:335\u201340.","journal-title":"Scand J Urol Nephrol"},{"key":"5579_CR10","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1016\/j.juro.2009.01.117","volume":"181","author":"MK Flynn","year":"2009","unstructured":"Flynn MK, Amundsen CL, Perevich M, Liu F, Webster GD. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol. 2009;181:2608\u201315.","journal-title":"J Urol"},{"key":"5579_CR11","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.juro.2007.05.136","volume":"178","author":"HC Kuo","year":"2007","unstructured":"Kuo HC. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J Urol. 2007;178:1359\u201363.","journal-title":"J Urol"},{"key":"5579_CR12","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/nau.24758","volume":"40","author":"EE Mensah","year":"2021","unstructured":"Mensah EE, Toia B, Nguyen L, et al. Intravesical onabotulinumtoxinA injections in patients on antiplatelet and anticoagulation therapy. Neurourol Urodyn. 2021;40:1829\u201333.","journal-title":"Neurourol Urodyn"},{"key":"5579_CR13","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/nau.24879","volume":"41","author":"JC Truzzi","year":"2022","unstructured":"Truzzi JC, Lapitan MC, Truzzi NC, Iacovelli V, Averbeck MA. Botulinum toxin for treating overactive bladder in men: a systematic review. Neurourol Urodyn. 2022;41:710\u201323.","journal-title":"Neurourol Urodyn"},{"key":"5579_CR14","doi-asserted-by":"publisher","first-page":"321","DOI":"10.12701\/yujm.2020.00353","volume":"37","author":"BE Park","year":"2020","unstructured":"Park BE, Bae MH, Kim HJ, et al. Perioperative outcomes of interrupted anticoagulation in patients with non-valvular atrial fibrillation undergoing non-cardiac surgery. J Yeungnam Med Sci. 2020;37:321\u20138.","journal-title":"J Yeungnam Med Sci"},{"key":"5579_CR15","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1001\/jamainternmed.2019.2431","volume":"179","author":"JD Douketis","year":"2019","unstructured":"Douketis JD, Spyropoulos AC, Duncan J, et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMA Intern Med. 2019;179:1469\u201378.","journal-title":"JAMA Intern Med"},{"key":"5579_CR16","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1159\/000351144","volume":"35","author":"C Weimar","year":"2013","unstructured":"Weimar C, Cotton D, Sha N, et al. Discontinuation of antiplatelet study medication and risk of recurrent stroke and cardiovascular events: results from the PRoFESS study. Cerebrovasc Dis. 2013;35:538\u201343.","journal-title":"Cerebrovasc Dis"},{"key":"5579_CR17","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1093\/eurheartj\/ehu282","volume":"35","author":"SD Kristensen","year":"2014","unstructured":"Kristensen SD, Knuuti J, Saraste A, et al. ESC\/ESA guidelines on non-cardiac surgery: cardiovascular assessment and management: the joint task force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J. 2014;35:2383\u2013431.","journal-title":"Eur Heart J"},{"key":"5579_CR18","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.ijcard.2015.09.035","volume":"202","author":"PL Mar","year":"2016","unstructured":"Mar PL, Familtsev D, Ezekowitz MD, Lakkireddy D, Gopinathannair R. Periprocedural management of anticoagulation in patients taking novel oral anticoagulants: review of the literature and recommendations for specific populations and procedures. Int J Cardiol. 2016;202:578\u201385.","journal-title":"Int J Cardiol"},{"key":"5579_CR19","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1007\/s00345-020-03078-2","volume":"38","author":"K Dimitropoulos","year":"2020","unstructured":"Dimitropoulos K, Omar MI, Chalkias A, Arnaoutoglou E, Douketis J, Gravas S. Perioperative antithrombotic (antiplatelet and anticoagulant) therapy in urological practice: a critical assessment and summary of the clinical practice guidelines. World J Urol. 2020;38:2761\u201370.","journal-title":"World J Urol"},{"key":"5579_CR20","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.mayocpiqo.2022.09.006","volume":"6","author":"S Shah","year":"2022","unstructured":"Shah S, Urtecho M, Firwana M, et al. Perioperative management of antiplatelet therapy: a systematic review and meta-analysis. Mayo Clin Proc Innov Qual Outcomes. 2022;6:564\u201373.","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"5579_CR21","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/bja\/aer274","volume":"107","author":"J Mantz","year":"2011","unstructured":"Mantz J, Samama CM, Tubach F, et al. Impact of preoperative maintenance or interruption of aspirin on thrombotic and bleeding events after elective non-cardiac surgery: the multicentre, randomized, blinded, placebo-controlled, STRATAGEM trial. Br J Anaesth. 2011;107:899\u2013910.","journal-title":"Br J Anaesth"},{"key":"5579_CR22","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.juro.2014.04.103","volume":"192","author":"DJ Culkin","year":"2014","unstructured":"Culkin DJ, Exaire EJ, Green D, et al. Anticoagulation and antiplatelet therapy in urological practice: ICUD\/AUA review paper. J Urol. 2014;192:1026\u201334.","journal-title":"J Urol"},{"key":"5579_CR23","doi-asserted-by":"publisher","first-page":"e26985","DOI":"10.1097\/MD.0000000000026985","volume":"100","author":"D Chen","year":"2021","unstructured":"Chen D, Liu G, Xie Y, Chen C, Luo Z, Liu Y. Safety of transrectal ultrasound-guided prostate biopsy in patients receiving aspirin: an update meta-analysis including 3373 patients. Medicine (Baltimore). 2021;100:e26985.","journal-title":"Medicine (Baltimore)"},{"key":"5579_CR24","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12894-017-0309-0","volume":"17","author":"T Konishi","year":"2017","unstructured":"Konishi T, Washino S, Nakamura Y, et al. Risks and complications of transurethral resection of bladder tumors in patients receiving antiplatelet and\/or anticoagulant therapy: a retrospective cohort study. BMC Urol. 2017;17:118.","journal-title":"BMC Urol"},{"key":"5579_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1055\/s-0039-1696945","volume":"46","author":"I Nikolakopoulos","year":"2020","unstructured":"Nikolakopoulos I, Spyropoulos AC. Heparin bridging therapy for patients on chronic oral anticoagulants in periprocedural settings. Semin Thromb Hemost. 2020;46:26\u201331.","journal-title":"Semin Thromb Hemost"},{"key":"5579_CR26","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1056\/NEJMoa1501035","volume":"373","author":"JD Douketis","year":"2015","unstructured":"Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373:823\u201333.","journal-title":"N Engl J Med"},{"key":"5579_CR27","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/clc.23336","volume":"43","author":"HC Kuo","year":"2020","unstructured":"Kuo HC, Liu FL, Chen JT, Cherng YG, Tam KW, Tai YH. Thromboembolic and bleeding risk of periprocedural bridging anticoagulation: a systematic review and meta-analysis. Clin Cardiol. 2020;43:441\u20139.","journal-title":"Clin Cardiol"},{"key":"5579_CR28","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/emermed-2015-204891","volume":"33","author":"CV Pollack Jr","year":"2016","unstructured":"Pollack Jr CV. Coagulation assessment with the new generation of oral anticoagulants. Emerg Med J 2016;33:423\u201330.","journal-title":"Emerg Med J"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-023-05579-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00192-023-05579-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-023-05579-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T14:04:20Z","timestamp":1697897060000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00192-023-05579-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,17]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["5579"],"URL":"https:\/\/doi.org\/10.1007\/s00192-023-05579-1","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"value":"0937-3462","type":"print"},{"value":"1433-3023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,17]]},"assertion":[{"value":"20 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}